Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ... 7thSpace Interactive (press release) Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B --cell ... |
